Hartenberg Holding is a 200 million EUR investment fund focused on investments in companies in the Central European Region, primarily Czech Republic, Slovakia, Poland, Germany and Austria.
Hartenberg Capital is the General Partner and Trustee for Hartenberg Holding. Hartenberg Capital manages the fund’s assets, seeks investment candidates, executes investment transactions, implements and manages the investment strategies in collaboration with company management and potentially exits investments made by Hartenberg Holding.
Our ambition is to become a respected and trusted investor in the region where we invest.
Our investment objective is to earn the best possible returns, at an appropriate level of risk and to rank among industry leaders in the returns for our shareholders.
Like a typical investment firm, we intend to follow a rigorous investment selection and management process to pursue superior returns for our investors. However, because we invest only our own money, we are able to differentiate ourselves in a number of ways:
Hartenberg’s business model focuses on people driving the process of change and repositioning, driving top-line growth while combining financial discipline with industrial expertise.
We consider the people in our organization as our key asset. The team, originating exclusively from the region where we invest, combines strong local investment and operational experience with best practices in terms of deal structuring and financing, and value creation capabilities.
We invest into businesses where we can add value as an activist shareholder, a catalyst to transform and grow businesses to become leaders in their core markets.
Hartenberg targets established businesses with strong market positions, clear competitive advantages and significant potential for future sales and earnings growth, within industries that are consolidating, growing or changing and can demonstrate well-defined realization alternatives.
An ideal company for us will:
It is key for us before becoming owners to ensure that management, and sometimes co-investors, share the same view on how to move the company forward.
We typically invest in companies with Enterprise Values from 40 million to 200 million EUR, which may require equity investments of 20 million to 100 million EUR. We will consider doing larger transactions through co-investments, and will also consider smaller investments as part of a buy and build strategy.
We prefer to be a long-term investor in companies we acquire. A typical time horizon for us will be more than five years, however, we may stay invested “forever” if the acquired company provides us with a sufficient dividend yield and reasonable capital gains potential.
We remain opportunistic in terms of shareholding types. We invest into controlling or co-controlling positions with strong corporate rights, provided that straightforward problem solving mechanisms are agreed in advance and guarantee fair treatment.
We prefer to invest into industries that we know from our past experience and which deal with the final consumer / customer: Retail, FMCG, Health-Care, Services, Utilities.
The fund will primarily target Central Europe - Czech Republic, Slovakia, Poland, Germany and Austria.
All investment decisions are based on the recommendation of Hartenberg Capital’s Investment Committee.
We consider people in our organization the key asset. The team, originating exclusively from the region where we invest, combines strong local investment and operational experience with the best practices in terms of deal structuring and financing, and value creation capabilities.
In their previous assignments Investment Professionals from Hartenberg Capital participated on following projects:
Hartenberg Holding (Hartenberg), a 200 million EUR Central European investment fund, has acquired majority shareholding in the leader in the segment of private gynecological clinics and reproductive medicine - Reprofit International s.r.o. and GynCentrum s.r.o. The acquisition is done via Hartenberg’s daughter company - FutureLife a.s.
Hartenberg Holding (Hartenberg), a 200 million EUR Central European investment fund has acquired majority shareholding in Imunoglukan s.r.o., and Pleuran s.r.o., (Imunoglukan), privately owned biotechnology companies, which has developed and successfully marketed the leading immune-support supplement, Imunoglukan P4H ® on the CEE markets.
Hartenberg Capital, the Trustee of a 200 million EUR investment fund focused on investments in companies in the Central European Region, officially starts its operations as of June, 1st 2013 .